FDA grants orphan drug designation to myelodysplastic syndrome drug

10/6/2013 | Pharmaceutical Business Review Online

Cornerstone Pharmaceuticals announced that CPI-613, its myelodysplastic syndrome drug, has been given orphan drug status by the FDA. The altered energy metabolism directed drug candidate is in Phase I, I/II and Phase II trials focused on hematologic malignancies and solid tumors.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA